Eisai Ltd., of Hatfield, UK, part of Eisai Co. Ltd., reported results of an interim analysis of the non-interventional EPOS (Eslicarbazepine acetate in Partial-Onset Seizure) study presented this week at the XXI European Congress on Epileptology in Stockholm, showing that once-daily Zebinix (eslicarbazepine acetate) retained seizure control and is well tolerated when given as an add-on to anti-epileptic monotherapy to adults in routine clinical practice.